Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556998 · ClinicalTrials.gov registry record · Phase 2
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
A Phase 2 study of Pharmacokinetics, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 9
- Study locations
NCT00556998 is a Phase 2 study of Pharmacokinetics that has completed, run by Pfizer. The registered enrollment target is 26 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT00556998, a Phase 2 study of Pharmacokinetics, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.
Conditions Studied
Interventions
- DRUG Voriconazole
Study Locations (9)
Tennessee
- Pfizer Investigational Site - Nashville
- Pfizer Investigational Site - Nashville
Texas
- Pfizer Investigational Site - Fort Worth
- Pfizer Investigational Site - Houston
Illinois
- Pfizer Investigational Site - Chicago
Louisiana
- Pfizer Investigational Site - New Orleans
North Carolina
- Pfizer Investigational Site - Durham
Ohio
- Pfizer Investigational Site - Cleveland
Oregon
- Pfizer Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556998
The ClinicalTrials.gov registry entry for NCT00556998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Voriconazole is the first listed.
NCT00556998 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Tennessee, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT00556998 about?
NCT00556998 is a clinical study titled "A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents". This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.
What is the current status of trial NCT00556998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-06. Estimated completion is 2009-12.
What conditions does trial NCT00556998 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT00556998?
The interventions under investigation include: Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00556998?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00556998 being conducted?
This trial has 9 study locations across Illinois, Louisiana, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.